A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific transgenic TCR; CD8α/β coreceptor; and FAS-41BB switch receptor in patients with advanced or metastatic solid tumors.

AFNT-211 - Affini-T Therap

https://meetings.asco.org/abstracts-presentations/252258/

Soumit Basu; Binaish Khan; Francis Payumo; Robert Wan; E. Gabriela Chiorean; Zhubin Gahvari; Joel Hecht; Michael Hurwitz; Rom Leidner; Heinz-Josef Lenz; Meredith Pelster; Salman Punekar; Adam Schoenfeld; Dan Zhao; Dirk Nagorsen

Apr 23, 2025